Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 388 matching trials from the live ClinicalTrials.gov search.
Conditions
Head and Neck Cancer, Lung Cancer
Interventions
filgrastim, cisplatin, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
18
States / cities
Flemington, New Jersey • Lakewood, New Jersey • Millville, New Jersey + 15 more
Conditions
Acneiform Rash, Papulopustular Eruption
Interventions
Triamcinolone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Pegfilgrastim-induced Back and Leg Pain
Interventions
Loratadine, placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
Brewer, Maine • Scarborough, Maine • York Village, Maine + 4 more
Conditions
Unresectable Locally Advanced NSCLC
Interventions
Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta
Drug
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
18 Years to 90 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Miami Beach, Florida
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Capmatinib, Spartalizumab, Docetaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Fayetteville, Arkansas
Conditions
Kaposi's Sarcoma, HIV Infections, HIV Seronegativity
Interventions
Bevacizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
Procedure · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
25 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Phase 4 Interventional Accepts healthy volunteers Results available

RHYTHM (Formerly Escape II Myocardium)

NCT01548768
Conditions
Rheumatoid Arthritis
Interventions
TNF inhibitors, DMARDs
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Non-small Cell Lung Cancer
Interventions
ZD1839, Docetaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Houston, Texas
Conditions
Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma
Interventions
Erlotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Coronary Artery Disease
Interventions
Iodixanol, Ioxaglate, Bivalirudin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Metastatic Triple Negative Breast Cancer
Interventions
Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle)., Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
20
States / cities
Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 17 more
Conditions
Breast Cancer
Interventions
HKI-272, Surgical Resection, Capecitabine, Ado-Trastuzumab Emtansine
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
18
States / cities
San Francisco, California • Washington D.C., District of Columbia • Baltimore, Maryland + 11 more
Conditions
Diabetic Macular Edema
Interventions
intravitreal ranibizumab 0.3 mg, dexamethasone intravitreal implant, Sham injection
Drug · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
56
States / cities
Beverly Hills, California • Huntington Beach, California • Loma Linda, California + 47 more
Conditions
Uterine Cervical Neoplasms
Interventions
Bintrafusp alfa
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas • Stanford, California + 8 more
Conditions
Estrogen Receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Male Breast Cancer, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions
anastrozole, pazopanib hydrochloride, therapeutic conventional surgery
Drug · Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Prostatic Neoplasms
Interventions
GM-CSF, thalidomide, docetaxel
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Conditions
Renal Cell Carcinoma
Interventions
Erlotinib hydrochloride, Sirolimus
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Cardiopulmonary Bypass
Interventions
Recombinant activated factor VII, Prothrombin Complex Concentrate
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 30 Days
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Terminated Phase 1Phase 2 Interventional Results available

A Factor IX Gene Therapy Study (FIX-GT)

NCT03369444
Conditions
Hemophilia B
Interventions
FLT180a
Biological
Lead sponsor
University College, London
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Spinal Surgery, Vascular Surgery
Interventions
rThrombin
Biological
Lead sponsor
ZymoGenetics
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Pasadena, California
Conditions
Stage II-IIIB Non-small Cell Lung Carcinoma
Interventions
Osimertinib 80 mg/40 mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Santa Rosa, California • Las Vegas, Nevada • White Plains, New York
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects

NCT03453060
Conditions
Thrombosis
Interventions
E-WE Thrombin- Dose 1, E-WE Thrombin- Dose 2, E-WE Thrombin- Dose 3, E-WE Thrombin- Dose 4, Placebo
Drug · Other
Lead sponsor
Aronora, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Aortic Coarctation
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
Up to 30 Days
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia